Is BMY a Smart Stock to Buy Now?
Understanding the Bullish Case for Bristol-Myers Squibb (BMY)
Bristol-Myers Squibb (BMY) is a leading global biopharmaceutical company that has built a strong reputation in the healthcare industry. As of March 26th, the stock was trading at $59.43, with a trailing P/E ratio of 16.61 and a forward P/E of 9.20 according to Yahoo Finance. This valuation suggests that BMY may be an attractive option for investors looking for value in the pharmaceutical sector.
Jirsak/Shutterstock.com
A Reliable Dividend-Paying Stock
One of the key factors that make BMY appealing to long-term investors is its consistent dividend payments. The company has maintained a 17-year streak of consecutive dividend increases, offering a current yield of 4.63% with an annual payout of $2.52 per share. This reliability is supported by strong free cash flow and profitability, making BMY a solid choice for income-focused investors.
Diversified Portfolio and Strong Revenue Streams
BMY’s diversified portfolio spans oncology, immunology, and cardiovascular diseases, providing a stable foundation for revenue generation. Established products such as Opdivo and Eliquis continue to deliver steady revenues despite patent expirations. Additionally, the company’s growth portfolio includes drugs like Reblozyl and Breyanzi, along with late-stage candidates such as milvexian and admilparant, which offer significant upside potential.
In 2024, BMY reported $48.3 billion in revenue, reflecting a 7% year-over-year increase. Non-GAAP EPS reached $1.15, showcasing resilient operational performance. Strategic partnerships with companies like BioNTech and AI-driven initiatives further enhance innovation and strengthen the company’s pipeline.
Investment in Innovation and Future Growth
BMY is committed to scientific innovation, investing heavily in research and development. The company plans to launch over ten new products by 2030, positioning itself for long-term growth. Institutional backing from major players such as Vanguard, BlackRock, and State Street underscores confidence in BMY’s strategy and financial stability.
While the company faces challenges such as generic competition and occasional setbacks, its diversified revenue streams and robust pipeline help mitigate risks. This combination of resilience and innovation provides a strong foundation for sustained growth and shareholder returns.
Analyst Outlook and Market Position
Analysts maintain a “Buy” consensus on BMY, with an average 12-month price target of $57.64, indicating moderate upside potential. For investors seeking a blend of steady dividends, strong fundamentals, and long-term growth, BMY presents a compelling opportunity with limited downside risk.
Additional Insights and Comparisons
Previously, a bullish thesis on BMY was highlighted by Magnus Ofstad in March 2025, focusing on the company’s high-risk, high-reward growth potential driven by its neuroscience drug Cobenfy and broader pipeline. Since then, BMY’s stock price has appreciated by approximately 0.72%.
Serhio MaxDividends shares a similar view but emphasizes BMY’s reliable dividend track record, diversified portfolio, and steady long-term growth. While BMY is not currently on the list of the 40 Most Popular Stocks Among Hedge Funds, it remains a notable holding, with 82 hedge fund portfolios holding BMY at the end of the fourth quarter, compared to 76 in the previous quarter.
Despite acknowledging the risks and potential of BMY as an investment, some investors may find greater promise in AI stocks, which are seen as having higher return potential within a shorter time frame. For those interested in exploring AI stocks with significant upside potential, there are opportunities worth considering.
